Webinar Series: Prostate Cancer & Cardiovascular Disease

Session #2: How have the recent clinical trials in Prostate Cancer informed my practice choices?

MODERATORS:
Juan Gómez Rivas
Hospital Clínico San Carlos in Madrid, Spain

Katie Zhang
UT Southwestern Medical Center, USA

SPEAKERS:
Ricardo Rendon
Dalhousie University, Halifax, CA
(Pivotal trials that have changed my practice)

Alicia Morgans
Dana-Farber Cancer Institute, USA 
(The role of different hormonal based therapies in Prostate Cancer)

Renato Lopes 
Duke Clinical Research Institute, USA
(Summarizing the CV toxicities for prostate cancer therapies, including the PRONOUNCE trial)

DESCRIPTION:

• The shifting landscape of hormonal therapy for advanced prostate cancer, with earlier implementation of androgen pathways
• How does real life treatment of prostate cancer differ from patients defined in clinical trials?
• How does optimal CVD management influence overall outcome?
• Collaboration across specialties? 
• How to monitor/minimize CV toxicity